Lido Advisors’s Immunome IMNM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.06M Buy
49,392
+51
+0.1% +$1.27K ﹤0.01% 1053
2026
Q2
$1.05M Buy
49,341
+391
+0.8% +$8.37K ﹤0.01% 1071
2026
Q1
$1.07M Sell
48,950
-10,101
-17% -$225K ﹤0.01% 942
2025
Q4
$691K Hold
59,051
– – ﹤0.01% 1153
2025
Q3
$691K Sell
59,051
-34
-0.1% -$338 ﹤0.01% 1095
2025
Q2
$549K Buy
59,085
+6,085
+11% +$49.9K ﹤0.01% 1080
2025
Q1
$357K Buy
+53,000
New +$508K ﹤0.01% 1142

Other funds holding IMNM

Lido Advisors's IMNM Position: Q3 2026 in Review

Lido Advisors increased its Immunome (IMNM) stake by 0.1% in Q3 2026, buying an estimated $1.27K and bringing the position to 49,392 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #1053.

Lido Advisors first reported a position in IMNM in Q1 2025 and has held it in 7 quarters since. The position peaked at $1.07M in Q1 2026. 211 funds tracked by Wall St. Rank hold IMNM as of Q3 2026.

  • Lido Advisors held 49,392 shares of Immunome worth $1.06M as of Q3 2026.
  • Lido Advisors bought 51 Immunome shares in Q3 2026, an estimated $1.27K.
  • Immunome made up ﹤0.01% of Lido Advisors's portfolio in Q3 2026, its #1053 holding.
  • Lido Advisors first reported a position in Immunome in Q1 2025 and has held it in 7 quarters since.
  • Lido Advisors's Immunome position peaked at $1.07M in Q1 2026.
  • 211 funds tracked by Wall St. Rank held Immunome as of Q3 2026.

Based on Lido Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.